BioPharma Resources

Drug Trial Radar · NCT07521631

Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes

A Phase 2, Randomized, Open-Label, Controlled Trial to Evaluate the Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 372 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

372

Planned (sponsor's estimate)

Start

Mar 31, 2026

Primary completion

Feb 4, 2027

Study completion Jul 23, 2027

Sponsor

Sponsor type
Industry
First posted
Apr 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 56-week randomized, open-label, controlled study evaluating the efficacy and safety of the HDM1005 compared to tirzepatide in adults with obesity but without diabetes. Eligible participants will be screened and randomized to different dose group of HDM1005 or the tirzepatide group at a ratio of 1:1:1 :1, HDM1005 or tirzepatide will be given once weekly for 52 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.

Conditions

  • Obesity

Interventions

  • HDM1005 dose level 1Drug

    Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose level 1, the intervention will last for 52 weeks in total.

  • HDM1005 dose level 2Drug

    Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose level 2, the intervention will last for 52 weeks in total.

  • HDM1005 dose level 3Drug

    Initiate at a once weekly dose of 0.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose level 3, the intervention will last for 52 weeks in total.

  • TirzepatideDrug

    Initiate at a once weekly dose of 2.5 mg and followed a dose escalation regimen, with dose increases every 4 weeks aiming at reaching the maintenance dose, the intervention will last for 52 weeks in total.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary OutcomeTime frame: week 40

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hoapital

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.